For common outcomes there was similar efficacy between PDE-5 inhibitors
Background There are no r and omised and properly blinded trials directly comparing one PDE-5 inhibitor with another in a normal home setting .
Valid indirect comparisons with a common comparator must examine equivalent doses , similar duration , similar population s , with the same outcomes reported in the same way .
Long-term efficacy and safety of oral Viagra® (sildenafil citrate) in men with erectile dysfunction and the effect of randomised treatment withdrawal
The long-term efficacy and safety of oral Viagra ® ( sildenafil citrate ) , a selective phosphodiesterase 5 inhibitor , and the effect of withdrawing treatment were evaluated in men with erectile dysfunction ( ED ) . In 233 men with ED of psychogenic or mixed organic/psychogenic aetiology , 16 weeks of open-label , flexible-dose sildenafil treatment ( 10–100 mg ) was followed by eight weeks of double-blind , fixed-dose , r and omised withdrawal to placebo or continued treatment with sildenafil . Sildenafil was taken as needed ( not more than once daily ) approximately 1 h prior to sexual activity . The main outcome measures were a global efficacy question , a sexual function question naire , an event log of erections , and adverse event recording . In the open-label phase , 200 of 216 patients ( 93 % ) reported improved erections  with sildenafil ; 28 patients ( 12 % ) discontinued treatment . In the double-blind phase , the significant improvements in the frequency and duration of erections were maintained in the sildenafil group but returned to pre-treatment values in patients on placebo ( P values<0.0001 versus placebo ) . The most frequent adverse events in the sildenafil group during the double-blind phase were flushing ( 7 % ) , headache ( 6 % ) , and dyspepsia ( 5 % ) . Of the 192 patients enrolled in the 1-y extension , 90 % completed the study ; only two patients ( 1 % ) were withdrawn due to lack of efficacy . In men with ED of psychogenic or mixed aetiology , oral sildenafil is effective and well-tolerated both at the initiation of therapy and during long-term treatment . For most patients , sildenafil treatment must be continued for improvements in erectile function to be maintained
For common outcomes there was similar efficacy between PDE-5 inhibitors
Background There are no r and omised and properly blinded trials directly comparing one PDE-5 inhibitor with another in a normal home setting .
Valid indirect comparisons with a common comparator must examine equivalent doses , similar duration , similar population s , with the same outcomes reported in the same way .